Annual Total Liabilities
$53.60 M
-$72.57 M-57.52%
December 31, 2023
Summary
- As of February 8, 2025, INO annual total liabilities is $53.60 million, with the most recent change of -$72.57 million (-57.52%) on December 31, 2023.
- During the last 3 years, INO annual total liabilities has fallen by -$25.03 million (-31.83%).
- INO annual total liabilities is now -61.31% below its all-time high of $138.55 million, reached on December 31, 2019.
Performance
INO Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$33.52 M
-$3.54 M-9.55%
September 30, 2024
Summary
- As of February 8, 2025, INO quarterly total liabilities is $33.52 million, with the most recent change of -$3.54 million (-9.55%) on September 30, 2024.
- Over the past year, INO quarterly total liabilities has dropped by -$20.08 million (-37.47%).
- INO quarterly total liabilities is now -86.95% below its all-time high of $256.82 million, reached on June 30, 2020.
Performance
INO Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
INO Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -57.5% | -37.5% |
| 3 y3 years | -31.8% | -79.3% |
| 5 y5 years | +21.6% | -79.3% |
INO Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -57.5% | at low | -79.3% | at low |
| 5 y | 5-year | -61.3% | at low | -87.0% | at low |
| alltime | all time | -61.3% | +4437.2% | -87.0% | +4164.6% |
Inovio Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $33.52 M(-9.5%) |
| Jun 2024 | - | $37.06 M(+6.9%) |
| Mar 2024 | - | $34.67 M(-35.3%) |
| Dec 2023 | $53.60 M(-57.5%) | $53.60 M(-2.4%) |
| Sep 2023 | - | $54.94 M(-13.7%) |
| Jun 2023 | - | $63.67 M(-5.5%) |
| Mar 2023 | - | $67.37 M(-46.6%) |
| Dec 2022 | $126.17 M(+31.1%) | $126.17 M(+0.7%) |
| Sep 2022 | - | $125.27 M(-22.5%) |
| Jun 2022 | - | $161.73 M(+78.9%) |
| Mar 2022 | - | $90.43 M(-6.1%) |
| Dec 2021 | $96.27 M(+22.4%) | $96.27 M(+17.1%) |
| Sep 2021 | - | $82.19 M(-1.3%) |
| Jun 2021 | - | $83.29 M(+13.7%) |
| Mar 2021 | - | $73.26 M(-6.8%) |
| Dec 2020 | $78.63 M(-43.2%) | $78.63 M(-30.9%) |
| Sep 2020 | - | $113.81 M(-55.7%) |
| Jun 2020 | - | $256.82 M(+70.0%) |
| Mar 2020 | - | $151.07 M(+9.0%) |
| Dec 2019 | $138.55 M(+214.3%) | $138.55 M(+20.0%) |
| Sep 2019 | - | $115.41 M(+6.3%) |
| Jun 2019 | - | $108.60 M(-1.5%) |
| Mar 2019 | - | $110.20 M(+150.0%) |
| Dec 2018 | $44.08 M(-1.5%) | $44.08 M(+19.2%) |
| Sep 2018 | - | $36.99 M(-1.2%) |
| Jun 2018 | - | $37.43 M(-38.2%) |
| Mar 2018 | - | $60.57 M(+35.4%) |
| Dec 2017 | $44.75 M(-11.1%) | $44.75 M(+7.7%) |
| Sep 2017 | - | $41.56 M(+17.7%) |
| Jun 2017 | - | $35.32 M(-25.4%) |
| Mar 2017 | - | $47.37 M(-5.9%) |
| Dec 2016 | $50.33 M(+32.8%) | $50.33 M(+5.8%) |
| Sep 2016 | - | $47.57 M(+13.5%) |
| Jun 2016 | - | $41.90 M(+4.6%) |
| Mar 2016 | - | $40.07 M(+5.7%) |
| Dec 2015 | $37.91 M(+87.2%) | $37.91 M(+1.4%) |
| Sep 2015 | - | $37.39 M(+80.2%) |
| Jun 2015 | - | $20.75 M(+43.8%) |
| Mar 2015 | - | $14.43 M(-28.7%) |
| Dec 2014 | $20.25 M(-42.8%) | $20.25 M(+15.8%) |
| Sep 2014 | - | $17.49 M(-12.1%) |
| Jun 2014 | - | $19.88 M(-11.5%) |
| Mar 2014 | - | $22.48 M(-36.5%) |
| Dec 2013 | $35.38 M(+244.2%) | $35.38 M(+37.2%) |
| Sep 2013 | - | $25.80 M(+21.0%) |
| Jun 2013 | - | $21.32 M(+19.9%) |
| Mar 2013 | - | $17.78 M(+72.9%) |
| Dec 2012 | $10.28 M(-22.4%) | $10.28 M(-22.1%) |
| Sep 2012 | - | $13.20 M(+7.8%) |
| Jun 2012 | - | $12.24 M(-19.1%) |
| Mar 2012 | - | $15.12 M(+14.2%) |
| Dec 2011 | $13.24 M | $13.24 M(+10.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2011 | - | $11.96 M(-2.6%) |
| Jun 2011 | - | $12.28 M(-26.1%) |
| Mar 2011 | - | $16.60 M(+85.1%) |
| Dec 2010 | $8.97 M(-53.9%) | $8.97 M(+15.2%) |
| Sep 2010 | - | $7.78 M(-6.5%) |
| Jun 2010 | - | $8.32 M(-59.2%) |
| Mar 2010 | - | $20.40 M(+4.9%) |
| Dec 2009 | $19.44 M(-2.2%) | $19.44 M(-12.6%) |
| Sep 2009 | - | $22.25 M(-12.4%) |
| Jun 2009 | - | $25.42 M(+26.0%) |
| Mar 2009 | - | $20.17 M(+1.4%) |
| Dec 2008 | $19.88 M(+127.5%) | $19.88 M(+109.7%) |
| Sep 2008 | - | $9.48 M(+9.0%) |
| Jun 2008 | - | $8.70 M(+7.1%) |
| Mar 2008 | - | $8.12 M(-7.1%) |
| Dec 2007 | $8.74 M(-29.8%) | $8.74 M(+4.9%) |
| Sep 2007 | - | $8.33 M(-0.0%) |
| Jun 2007 | - | $8.33 M(+2.0%) |
| Mar 2007 | - | $8.17 M(-34.4%) |
| Dec 2006 | $12.45 M(+126.0%) | $12.45 M(+210.4%) |
| Sep 2006 | - | $4.01 M(-3.7%) |
| Jun 2006 | - | $4.17 M(-8.8%) |
| Mar 2006 | - | $4.57 M(-17.1%) |
| Dec 2005 | $5.51 M(+2.0%) | $5.51 M(+35.6%) |
| Sep 2005 | - | $4.06 M(-21.6%) |
| Jun 2005 | - | $5.18 M(-8.4%) |
| Mar 2005 | - | $5.65 M(+4.6%) |
| Dec 2004 | $5.40 M(+357.3%) | $5.40 M(+64.8%) |
| Sep 2004 | - | $3.28 M(+78.0%) |
| Jun 2004 | - | $1.84 M(+119.1%) |
| Mar 2004 | - | $840.20 K(-28.9%) |
| Dec 2003 | $1.18 M(-30.3%) | $1.18 M(+14.1%) |
| Sep 2003 | - | $1.04 M(+31.7%) |
| Jun 2003 | - | $786.00 K(-14.3%) |
| Mar 2003 | - | $916.80 K(-45.9%) |
| Dec 2002 | $1.69 M(+1.4%) | $1.69 M(+31.8%) |
| Sep 2002 | - | $1.29 M(+4.5%) |
| Jun 2002 | - | $1.23 M(-10.4%) |
| Mar 2002 | - | $1.37 M(-5.7%) |
| Dec 2001 | $1.67 M(+4.7%) | - |
| Sep 2001 | - | $1.46 M(-8.1%) |
| Jun 2001 | - | $1.58 M(-0.8%) |
| Mar 2001 | - | $1.60 M(-2.2%) |
| Mar 2001 | $1.60 M(-26.8%) | - |
| Dec 2000 | - | $1.63 M(-0.8%) |
| Sep 2000 | - | $1.65 M(-18.8%) |
| Jun 2000 | - | $2.03 M(-7.1%) |
| Mar 2000 | $2.18 M(+44.7%) | $2.18 M(+3.9%) |
| Dec 1999 | - | $2.10 M(+16.7%) |
| Sep 1999 | - | $1.80 M(+28.6%) |
| Jun 1999 | - | $1.40 M(-7.1%) |
| Mar 1999 | $1.51 M | $1.51 M(+16.0%) |
| Dec 1998 | - | $1.30 M |
FAQ
- What is Inovio Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals annual total liabilities year-on-year change?
- What is Inovio Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Inovio Pharmaceuticals?
- What is Inovio Pharmaceuticals quarterly total liabilities year-on-year change?
What is Inovio Pharmaceuticals annual total liabilities?
The current annual total liabilities of INO is $53.60 M
What is the all time high annual total liabilities for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high annual total liabilities is $138.55 M
What is Inovio Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, INO annual total liabilities has changed by -$72.57 M (-57.52%)
What is Inovio Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of INO is $33.52 M
What is the all time high quarterly total liabilities for Inovio Pharmaceuticals?
Inovio Pharmaceuticals all-time high quarterly total liabilities is $256.82 M
What is Inovio Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, INO quarterly total liabilities has changed by -$20.08 M (-37.47%)